ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Healing potential of curcumin gel in experimental wounds infected with resistant Pseudomonas aeruginosa: a comparative study with silver sulfadiazine.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug‑resistant Pseudomonas aeruginosa poses a major challenge in wound care, with standard therapy such as silver sulfadiazine (SSD) increasingly limited by cytotoxic side effects. Curcumin, a polyphenolic compound from Curcuma longa, offers a biocompatible alternative with established antibacterial, anti‑inflammatory, and wound healing properties. This study compared the therapeutic efficacy of a topical curcumin gel with 1% SSD cream in MDR P. aeruginosa-infected excision wounds in rabbits. Twenty‑five male New Zealand white rabbits were divided into five groups: negative control, positive control, curcumin gel, SSD, and carbopol vehicle. Outcomes were assessed over 21 days by in vitro antibacterial activity, wound contraction, serum IL‑6 levels, and histopathological/histomorphometry analysis. Curcumin exhibited dose‑dependent antibacterial activity, with an inhibition zone of 14.09 mm at 2.0 MIC, comparable to SSD (15.44 mm). In vivo, curcumin gel achieved the highest early wound contraction at day 7 (62.06% vs. 46.14% for SSD), with final closure comparable between treatments (96.44% vs. 99.24%). Curcumin suppressed the pathological IL‑6 surge more effectively than SSD at day 14, confirming its dual antibacterial and NF‑κB‑mediated anti‑inflammatory effects. Histopathology revealed early vascular granulation (day 7), collagen remodeling (day 14), and complete organized re‑epithelialization with folliculogenesis and minimal inflammation by day 21. Epithelial thickness in the curcumin group (40.20 µm) was statistically similar to SSD (39.74 µm) and superior to controls. Overall, curcumin gel demonstrated potent antibacterial activity, superior early wound healing kinetics, effective immunomodulation, and complete tissue restoration, highlighting its preclinical potential as a biocompatible and efficacious alternative to SSD for MDR-infected wounds, warranting further clinical validation.
Indexed as
Identifiers
42744921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.